E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the feasibility of administration of a single dose of
E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery)
of locoregionally advanced HPV-associated cancers. The intent of E7 TCR-T cell treatment is
to shrink or eliminate tumors and thereby facilitate definitive therapy and increase overall
survival.
This study seeks to determine 1) if E7 TCR-T cell can be administered without undue delay in
definitive treatment, 2) the tumor response rate to E7 TCR-T cell treatment, 3) and the
disease-free survival rate at 2 and 5 years.
Participants will undergo an apheresis procedure to obtain T cells that will be genetically
engineered to generate E7 TCR-T cells. They will receive a conditioning regimen, a single
infusion of their own E7 TCR-T cells, and adjuvant aldesleukin. Participants will follow up
to assess safety and determine tumor response and will return to their primary oncology team
for definitive therapy.